Company Marizyme, Inc. Other OTC
Equities
GBSX
US5703721028
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Life Science Technologies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +176.60% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +176.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Barthel
CEO | Chief Executive Officer | 67 | 15/11/21 |
George Kovalyov
DFI | Director of Finance/CFO | 39 | 20/12/21 |
Chairman | 71 | 21/02/21 | |
Donald Very
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/12/20 |
Catherine Pachuk
CTO | Chief Tech/Sci/R&D Officer | 68 | 30/06/20 |
Harrison Ross
IRO | Public Communications Contact | 33 | 22/12/21 |
Amar Dhaduk
PRN | Corporate Officer/Principal | - | 31/12/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Barthel
CEO | Chief Executive Officer | 67 | 15/11/21 |
Chairman | 71 | 21/02/21 | |
Terry Brostowin
BRD | Director/Board Member | 65 | 13/12/18 |
Nilesh Patel
BRD | Director/Board Member | 59 | 21/04/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 131,793,088 | 85,723,766 ( 65.04 %) | 0 | 65.04 % |
Company contact information
![address Marizyme, Inc.(GBSX)](https://cdn.zonebourse.com/static/address/13303515.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.44% | 122B | |
+18.94% | 113B | |
+18.52% | 26.22B | |
-25.37% | 19.01B | |
-19.98% | 15.71B | |
-20.20% | 15.22B | |
-47.37% | 14.72B | |
+59.91% | 14.58B | |
+4.35% | 13.84B |